Trevena
Clinical stage biopharmaceutical company discovering and developing g-protein coupled receptors (gpcr) biased ligands.
Launch date
Employees
Market cap
€4.6m
Enterprise valuation
€23m (Public information from Sep 2024)
Share price
$4.7 TRVN
Upper Merion Township Pennsylvania (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 3.1m | <1m | (<1m) | - | <1m | 9.0m | - |
| % growth | 9800 % | (82 %) | (174 %) | - | - | 2883 % | - |
| EBITDA | (29.5m) | (51.9m) | (56.4m) | - | - | - | - |
| % EBITDA margin | (961 %) | (9158 %) | 13487 % | - | - | - | - |
| Profit | (29.4m) | (51.6m) | (53.7m) | (32.7m) | (25.7m) | (20.9m) | (31.8m) |
| % profit margin | (957 %) | (9098 %) | 12839 % | - | (8567 %) | (234 %) | - |
| EV / revenue | 109.5x | 169.0x | -26.4x | - | 11.2x | 0.4x | - |
| EV / EBITDA | -11.4x | -1.9x | -0.2x | - | - | - | - |
| R&D budget | 13.1m | 13.4m | 18.2m | - | - | - | - |
| R&D % of revenue | 428 % | 2368 % | (4357 %) | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
* | $15.0m | Post IPO Equity | |
* | N/A | $15.0m | Post IPO Debt |
* | N/A | $4.0m | Private Placement VC |
* | N/A | $1.9m | Private Placement VC |
* | $2.0m | Post IPO Debt | |
| Total Funding | €123m | ||